Faruqi & Faruqi, LLP is investigating the claims on behalf of investors Pacire Investing.com
Faruqi & Faruqi, LLP securities litigation partner James (Josh) Wilson He encourages investors who have suffered losses in excess of $75,000 in Pacira to contact him directly to discuss their options
If you suffered losses greater than $75,000 in Pacira between August 2, 2023 and August 8, 2024 and want to discuss your legal rights, call a Faruqi & Faruqi partner Josh Wilson direct on 877-247-4292 or 212-983-9330 (ext. 1310).
[You may also click here for additional information]
New York, New York–(Newsfile Corp. – January 19, 2025) – Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pacira BioSciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX ) and reminds investors of The deadline is March 14, 2025 to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The company has recovered hundreds of millions of dollars for investors since its inception in 1995. See www.faruqilaw.com.
According to the complaint, on August 9, 2024, Pacira announced that the District Court of New Jersey had invalidated its ‘495 patent, holding that eVenus did not infringe the ‘495 patent based on obviousness and anticipation. The lawsuit states that this decision was made shortly after Pacira submitted additional evidence to the court, which the court stated would have no impact on the basis of the decision. The complaint further alleges that this ruling was secondary to a ruling by the same court that affected the construction of Pacira’s ‘495 and ‘336 patent claims in favor of eVenus.
According to the complaint, Pacira’s announcement that its ‘495 patent had been invalidated surprised both investors and analysts as they reacted immediately to the revelations. The lawsuit alleges that the price of Pacira’s common stock fell dramatically. According to the lawsuit, from a closing market price of $22.36 per share on August 8, 2024, Pacira’s stock price fell to a low of $11.70 per share on August 9, 2024, a drop of over 47% in one day. thereby harming investors.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of the class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may propose to the Court to serve as lead plaintiff through counsel of his or her choosing, or may choose to do nothing and remain an absent class member. Your ability to participate in any recovery is not affected by the decision whether or not you will be the lead plaintiff.
Faruqi & Faruqi, LLP also encourages anyone with information about Pacira’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Follow us for updates on LinkedIn, on X or on Facebook (NASDAQ:).
Advertising of lawyers. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Past results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your specific case. All communications will be treated confidentially.
To view the original version of this press release, visit https://www.newsfilecorp.com/release/237458
